Ranolazine Cardioprotection in PCI

• Status: Terminated
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Harvey Hahn
• Collaborator: Gilead Sciences
• Treatments: Ranolazine

Criteria

Inclusion Criteria:

• Age 18 or older

• Patients undergoing Coronary Angiography with possible PCI

• Able and willing to give consent

• Able to read and write English

Exclusion Criteria:

• Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary Syndromes (ACS)

• History of Allergy to Ranolazine

• Pregnant or Nursing

• Currently taking Ranolazine